145 related articles for article (PubMed ID: 36636586)
1. Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.
Koenig MK; Russo SN; McBride KL; Bjornsson HT; Gunnarsdottir BB; Goldstein A; Falk SA
JIMD Rep; 2023 Jan; 64(1):65-70. PubMed ID: 36636586
[TBL] [Abstract][Full Text] [Related]
2. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.
Sabbah HN
Heart Fail Rev; 2022 Sep; 27(5):1911-1923. PubMed ID: 34623544
[TBL] [Abstract][Full Text] [Related]
3. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
Reid Thompson W; Hornby B; Manuel R; Bradley E; Laux J; Carr J; Vernon HJ
Genet Med; 2021 Mar; 23(3):471-478. PubMed ID: 33077895
[TBL] [Abstract][Full Text] [Related]
4. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.
Karaa A; Haas R; Goldstein A; Vockley J; Weaver WD; Cohen BH
Neurology; 2018 Apr; 90(14):e1212-e1221. PubMed ID: 29500292
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Thompson WR; Manuel R; Abbruscato A; Carr J; Campbell J; Hornby B; Vaz FM; Vernon HJ
Genet Med; 2024 Apr; 26(7):101138. PubMed ID: 38602181
[TBL] [Abstract][Full Text] [Related]
6. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
Karaa A; Haas R; Goldstein A; Vockley J; Cohen BH
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):909-918. PubMed ID: 32096613
[TBL] [Abstract][Full Text] [Related]
7. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Hornby B; Thompson WR; Almuqbil M; Manuel R; Abbruscato A; Carr J; Vernon HJ
Orphanet J Rare Dis; 2022 Sep; 17(1):336. PubMed ID: 36056411
[TBL] [Abstract][Full Text] [Related]
8. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
Van den Eynde J; Chinni B; Vernon H; Thompson WR; Hornby B; Kutty S; Manlhiot C
Orphanet J Rare Dis; 2023 Apr; 18(1):76. PubMed ID: 37041653
[TBL] [Abstract][Full Text] [Related]
9. Elamipretide Promotes Mitophagosome Formation and Prevents Its Reduction Induced by Nutrient Excess in INS1 β-cells.
Petcherski A; Trudeau KM; Wolf DM; Segawa M; Lee J; Taddeo EP; Deeney JT; Liesa M
J Mol Biol; 2018 Dec; 430(24):4823-4833. PubMed ID: 30389435
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Alterations Caused by Defective Cardiolipin Remodeling in Inherited Cardiomyopathies.
Wasmus C; Dudek J
Life (Basel); 2020 Nov; 10(11):. PubMed ID: 33187128
[TBL] [Abstract][Full Text] [Related]
11. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
13. Targeting mitochondrial dysfunction with elamipretide.
Obi C; Smith AT; Hughes GJ; Adeboye AA
Heart Fail Rev; 2022 Sep; 27(5):1925-1932. PubMed ID: 35037146
[TBL] [Abstract][Full Text] [Related]
14. Current and future treatment approaches for Barth syndrome.
Thompson R; Jefferies J; Wang S; Pu WT; Takemoto C; Hornby B; Heyman A; Chin MT; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):17-28. PubMed ID: 34713454
[TBL] [Abstract][Full Text] [Related]
15. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
Bertero E; Kutschka I; Maack C; Dudek J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
[TBL] [Abstract][Full Text] [Related]
16. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.
Saad A; Herrmann SMS; Eirin A; Ferguson CM; Glockner JF; Bjarnason H; McKusick MA; Misra S; Lerman LO; Textor SC
Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28916603
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial cardiolipin involved in outer-membrane protein biogenesis: implications for Barth syndrome.
Gebert N; Joshi AS; Kutik S; Becker T; McKenzie M; Guan XL; Mooga VP; Stroud DA; Kulkarni G; Wenk MR; Rehling P; Meisinger C; Ryan MT; Wiedemann N; Greenberg ML; Pfanner N
Curr Biol; 2009 Dec; 19(24):2133-9. PubMed ID: 19962311
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Barth Syndrome by Cardiolipin Manipulation (CARDIOMAN) With Bezafibrate: Protocol for a Randomized Placebo-Controlled Pilot Trial Conducted in the Nationally Commissioned Barth Syndrome Service.
Dabner L; Pieles GE; Steward CG; Hamilton-Shield JP; Ness AR; Rogers CA; Bucciarelli-Ducci C; Greenwood R; Ellis L; Sheehan K; Reeves BC
JMIR Res Protoc; 2021 May; 10(5):e22533. PubMed ID: 34057417
[TBL] [Abstract][Full Text] [Related]
19. Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations.
Daneshgar N; Liang PI; Lan RS; Horstmann MM; Pack L; Bhardwaj G; Penniman CM; O'Neill BT; Dai DF
Kidney Int; 2022 May; 101(5):906-911. PubMed ID: 34953771
[TBL] [Abstract][Full Text] [Related]
20. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
